)
Visual
test
Shield Therapeutics
Shield Therapeutics (STX) investor relations material
Shield Therapeutics Q4 2025 TU earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q4 2025 TU earnings summary22 Jan, 2026
Executive summary
Achieved cash flow positive status in Q4 2025, driven by strong US ACCRUFeR/ACCRUFERⓇ sales and effective cost management, marking a key milestone toward sustainability.
ACCRUFeR/ACCRUFERⓇ became the number one branded prescription oral iron in the US ID/IDA market, with a highly tolerable proprietary formulation.
Expanded global footprint with launches in Canada and regulatory progress in Korea, China, and pediatric populations.
Focused on expanding market share through direct-to-consumer and physician-targeted marketing, with emphasis on primary care, women's health, and digital outreach.
Actively pursuing a second product to leverage the existing sales force and further diversify the portfolio.
Financial highlights
Total 2025 revenues reached approximately $50 million, with $46 million from US ACCRUFeR/ACCRUFERⓇ sales, representing 56% year-over-year growth.
Nearly 200,000 prescriptions dispensed in 2025, up 33% year-over-year.
Net selling price per prescription increased 21% year-over-year to approximately $223 in 2025; Q4 2025 net selling price was $222.
Q4 2025 US revenues were $13.5 million, with 61,000 prescriptions, including 21% consignment at subsidized prices.
Ended Q4 2025 with $11.6 million in cash and cash equivalents, generating $1 million in net cash (excluding $2 million debt refinancing).
Outlook and guidance
Expect to remain cash flow positive and achieve EBIT/operating profitability for full year 2026, supported by continued ACCRUFeR/ACCRUFERⓇ growth.
Pricing for ACCRUFeR/ACCRUFERⓇ anticipated to fluctuate between $222 and $240 per prescription in 2026.
Targeting continued growth in prescriptions and revenues, with a focus on expanding into additional specialties and launching pediatric and international indications.
Peak US sales target for ACCRUFeR/ACCRUFERⓇ remains at $450 million, with further growth expected from new indications and expanded prescriber base.
Actively seeking to add a late-stage or FDA-approved specialty product to the portfolio.
What drives 2026 operating profit expectation
Why did Q4 net selling price decrease
How much of the $2.3B market is captured
Cash flow positive: How does this enable portfolio diversification
U.S. revenue growth slowing, script growth strong. Why?
Which new market/indication offers biggest upside?
Partial view of Summaries dataset, powered by Quartr API
Research faster. Power your platform.
Latest summaries
- TimeTickerHeadlineOpen
- 7 FebSBIN
Q3 FY26 net profit hit ₹21,028.15 crore, driven by robust growth and strategic divestments. - 7 FebGICRE
Net profit for the nine months surged to ₹6,62,217 lakhs, with a robust solvency ratio of 3.87. - 7 Feb517271
Strong revenue and profit growth, interim dividend, and major investments approved. - 7 Feb514167
Quarterly and nine-month results reflect solid revenue, profit, and compliance with new labour codes. - 7 FebMGL
Strong revenue growth offset by lower margins and profit; interim dividend declared. - 7 FebPGIL
Strong revenue and margin growth, with India set for further expansion and upgraded ratings. - 7 Feb504614
Strong revenue and profit growth in Q3 FY26, led by power and steel segments. - 7 FebCHEMPLASTS
Net losses widened and revenue fell year-over-year amid regulatory and market headwinds. - 6 FebHTOO
Resale registration for 71,429 shares via warrant, with proceeds only on exercise; financial risks persist. - 6 FebVSAT
Q3 revenue up 3% to $1.16B, net income $25M, strong cash flow, Ligado boost, satellite focus.
Next Shield Therapeutics earnings date
H2 202523 Apr, 2026
Shield Therapeutics
Next Shield Therapeutics earnings date
H2 202523 Apr, 2026
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
Shield Therapeutics plc is a specialty pharmaceutical company focused on the development and commercialization of treatments for iron deficiency and related conditions. The company's lead product, Accrufer/Feraccru® (ferric maltol), is an oral iron therapy designed to treat iron deficiency in patients who cannot tolerate traditional iron supplements. Shield Therapeutics operates in Europe and the United States, partnering with healthcare providers and pharmaceutical distributors to expand its market reach. The company is headquartered in Gateshead, United Kingdom, and its shares are listed on the AIM.
Quartr provides global coverage of all investor relation material from public companies.
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Yes, the Quartr mobile app is free on both iOS and Android.
Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.
Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.
Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.
Explore our global coverage